Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Science Wire.
Press releases published on August 14, 2025
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
August 14, 2025
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on …
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track …
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
August 14, 2025
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and …
3 E Network Announces Strategic Intent to Seize Opportunities in the New Compliance-Driven Stablecoin Era
GlobeNewswire
·
August 14, 2025
Hong Kong, China, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, today announced its strategic …
MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
GlobeNewswire
·
August 14, 2025
Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 …
Jonathan Low Named Forbes 40 Under 40 for Tech Innovation and Global Finance Impact
GlobeNewswire
·
August 14, 2025
Dubai, UAE, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Jonathan Low, founder of Biptap and a driving force in global finance, fintech, and Web3, has earned a spot on Forbes’ prestigious 40 Under 40 list in Tech. This honor cements his reputation as a visionary …
DogWalker Announces DOGWALK Token Pre-Sale, Transforming Blockchain Pet Care
GlobeNewswire
·
August 14, 2025
Marbella, Spain, Aug. 14, 2025 (GLOBE NEWSWIRE) -- DogWalker has officially launched the pre-sale of the DOGWALK Token (DWT). The project describes itself as the first fully blockchain-integrated dog walking and pet care ecosystem. Built for real-world …
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
August 14, 2025
Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work …
reAlpha Tech Corp. Announces 1,909% Year-over-Year Revenue Growth for Quarter Ended June 30, 2025
GlobeNewswire
·
August 14, 2025
DUBLIN, Ohio, Aug. 14, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial results and business highlights for the quarter ended June 30, 2025. …
EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation
GlobeNewswire
·
August 14, 2025
First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development Phase 1 Clinical Trial of EVOLVE104 to be Initiated in 2025 BRANFORD, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company …
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and …
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. …
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
GlobeNewswire
·
August 14, 2025
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 …
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp …
Infinity Loop Raises $5M; Empowers Enterprises to Save Millions on Vendor Contracts
GlobeNewswire
·
August 14, 2025
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Infinity Loop, the AI-native contract intelligence platform built to help enterprises save money on vendor contracts, today announced it has raised a $5M Seed Round, led by Glasswing Ventures and TIAA Ventures, …
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
GlobeNewswire
·
August 14, 2025
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …
SYLOGIST Reports Second Quarter 2025 Results
GlobeNewswire
·
August 14, 2025
Q2 2025 Highlights 1 Revenue (in $ millions) SaaS Subscription Recurring Total Reported Y/Y growth Reported Y/Y growth Reported Y/Y growth $7.9 13.1% $10.9 4.0% $15.7 (6.9)% SaaS ARR up 12.5% Y/Y to $31.7 million; Total ARR up 3% Y/Y to $43.8 million …
Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements
GlobeNewswire
·
August 14, 2025
NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company at the forefront of the cannabis, beverage, and wellness …
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 14, 2025
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of …
BTCS Reports Q2 2025 Results
GlobeNewswire
·
August 14, 2025
Record Quarterly Revenue of $2.77 million Post-Quarter ETH Holdings Surpass $321 Million SILVER SPRING, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain …